Safety and efficacy of rilzabrutinib vs placebo in adults with immune thrombocytopenia: the phase 3 LUNA3 study.

Rilzabrutinib is a covalent, reversible BTK inhibitor with multiple mechanisms targeting key immune thrombocytopenia (ITP) disease pathophysiology. The phase 3 LUNA3 study in previously treated adults with persistent/chronic ITP evaluated oral rilzabrutinib 400 mg bid (n=133) vs placebo (n=69) for 24 weeks. At baseline overall, median age was 47 years (range, 18-80), 63% female, 7.

Young-onset metastatic colorectal cancer: an opportunity and a vision for progress in cancer.

Metastatic young-onset colorectal cancer (yo-CRC) is a distinct and aggressive disease subtype that is becoming increasingly prevalent worldwide with Australia leading the world in this trend. This article provides an evidence-based perspective, through the prism of authors' personal experience, to craft an effective pathway not only to deliver improved outcomes for the patients but also to reduce disparities and foster collaboration amongst the cancer-treating community and indeed patients. It highlights an opportunity to re-define, re-design, and create a model that is rewarding to patients and cancer-treating community.

Extemporaneous compounding in Australian community pharmacies: extent, nature, and opinions.

Objectives: This study explores the extent and nature of compounding practices, and the relevant experiences and opinions of pharmacists within Australian community pharmacies.

Methods: A cross-sectional observational study was conducted using a self-administered survey that was emailed to 3349 Australian community pharmacies. The survey collected information on the extent and nature of compounding, as well as the experiences and opinions of pharmacists, using Likert scales and free-text responses.

Predicting outcomes of expectant and medical management in early pregnancy miscarriage using machine learning to develop and validate multivariable clinical prediction models.

Objective: To determine whether readily available patient, ultrasound and treatment outcome data can be used to develop, validate and externally test two machine learning (ML) models for predicting the success of expectant and medical management of miscarriage respectively.

Methods: A retrospective, multi-site study of patients opting for expectant or medical management of miscarriage was undertaken. A total of 1075 patients across two hospital early pregnancy units were eligible for inclusion.

Platelet autoantibodies have an impact on the platelet count in patients.

Background: It is widely accepted that autoantibodies directed against platelet glycoproteins (GP) are a major pathophysiological mechanism in immune thrombocytopenia (ITP), but little clinical data is available demonstrating an association between platelet antibodies and platelet counts.

Objectives: We hypothesized that if platelet antibodies are clinically relevant, number of targeted glycoproteins and antibody concentration should be associated with the extent of thrombocytopenia.

Methods: Platelet antibodies were identified in a direct, GP-specific test that detects antibodies against GP IIb/IIIa and GP Ib/IX.